

FOR IMMEDIATE RELEASE

29 July 2025

New guidelines released for the management of patients with endometrial carcinoma

ESGO-ESTRO-ESP joint guidelines reflect improved understanding of the complex nature of endometrial carcinoma

The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) have released [new evidence-based guidelines](#) for the treatment of endometrial carcinoma. These guidelines are an update from the prior guidelines published in 2021 and cover all relevant aspects of diagnosis, management, follow-up and patient education.

Importantly, they consider the large body of new evidence in this field and incorporate the 2023 update to the International Federation of Gynecology and Obstetrics (FIGO), which reflects the improved understanding of the complex nature of the different types of endometrial carcinoma and their underlying biological behaviour.

These guidelines are the result of 18 months' worth of work and were drafted by an international multidisciplinary panel of physicians comprising of 30 experts from gynaecological oncology, radiation oncology, medical oncology and pathology. The guidelines then underwent a comprehensive independent review by 225 experts from across Asia, Europe, North Africa, North America, the Middle East and South America. One patient representative was involved in the development of the guidelines and three in the review process – ensuring the patient perspective was integrated.

The guidelines aim to support clinicians in harmonising treatment and emphasise the importance of multidisciplinary teams and centralised care. They provide valuable guidance for the diverse range of disciplines involved in the treatment of endometrial carcinomas and will be updated in future based on new evidence as needed.

Prof. Nicole Concin, lead author and past president of ESGO, said “The perception of endometrial carcinoma has changed significantly in recent years. We now understand that it comprises at least four molecularly defined diseases, each with distinct clinical presentations and prognoses.”

“We are on a journey from a one-size-fits-all approach to an individualised therapeutic strategy tailored to each patient – based on the distinct biology of their tumour. The goal of this precision medicine approach is to avoid both over- and undertreatment.”

Prof. Xavier Matias-Guiu Guia, co-author and president-elect of the ESP, added “The ESGO-ESTRO-ESP update will foster the application of molecular pathology across the world – ultimately leading to better management of patients with endometrial carcinoma.”

Prof. Remi Nout, lead ESTRO representative, shared “These joint societal guidelines acknowledge the importance of an integrated, multidisciplinary approach to the management of endometrial cancer, and incorporate meaningful patient representation.”

Read the full guidelines: [https://www.thelancet.com/journals/lanoc/article/PIIS1470-2045\(25\)00167-6/fulltext](https://www.thelancet.com/journals/lanoc/article/PIIS1470-2045(25)00167-6/fulltext)

About ESGO

The European Society of Gynaecological Oncology (ESGO) is a not-for-profit association established in 1983. ESGO’s aim is to improve the health and well-being of women with gynaecological cancers through advocacy, prevention, research, excellence in care and education. Since its formation, ESGO has developed a strong infrastructure of 3000+ members and a network of early-career doctors, patient advocacy groups, centres of excellence and a variety of research groups across Europe and globally.

About ESTRO

The European Society for Radiotherapy and Oncology (ESTRO) is a non-profit scientific organisation dedicated to advancing cancer treatment through radiotherapy and multimodal approaches. ESTRO promotes education, science, and research, and advocates for equitable access to radiotherapy. With nearly 10,000 members across the globe, ESTRO supports radiation oncology professionals and the broader oncology community in delivering high-quality care.

About ESP

As the leading force in European pathology, the European Society of Pathology (ESP) promotes high quality pathology diagnosis for all patients, up-to-date education across Europe and supports cutting-edge research to understand disease and translate science into clinical practice.

Media Contact

Radka Škraňka Hlaváčková
Senior Marketing and Communications Manager
radka.skranka@esgo.org